3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Urologic Diseases
2
Urinary Bladder Neoplasms
2
Urinary Bladder Diseases
2
Carcinoma, Transitional Cell
2
Interventions
pembrolizumab
26
atezolizumab
14
Nivolumab
13
Gemcitabine
13
Cisplatin
10
Docetaxel
8
Carboplatin
8
avelumab
7
Mitomycin
7
epacadostat
4
cabozantinib
4
Ipilimumab
4
pemigatinib
3
Specimen Handling
3
Paclitaxel
3
Magnetic Resonance Spectroscopy
3
Bevacizumab
3
vofatamab
2
rucaparib
2
lenvatinib
2
enfortumab vedotin
2
durvalumab
2
cabazitaxel
2
bempegaldesleukin
2
Standard of Care
2
Rogaratinib
2
Ramucirumab
2
Radiation
2
Platinum
2
Pemetrexed
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma, Transitional Cell
×
B701 protein, Human herpesvirus 6
×
Clear all
NCT03123055
2020-03-18
FIERCE-22
Rainier Therapeutics
Phase 1/2
Terminated
28 enrolled
8 charts
NCT02401542
2020-03-09
FIERCE-21
Rainier Therapeutics
Phase 1/2
Terminated
71 enrolled
9 charts